Loading stock data…
CERS
$2.58-0.02 (-0.77%)
After Hours$2.57-0.01 (-0.39%)· Last close Jun 9
Cerus Corporation operates as a biomedical products company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cerus Corporation in the Healthcare sector is trading at $2.58. Wall Street consensus targets $4.67 (3 analysts), implying a +80.9% move over the next 12 months. The stock is currently 18% below its 52-week high of $3.15, remaining 31.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +80.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.58
Potential Downside
0%
Whystock Fair Value$2.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.14%
Volume
Today's trading volume
2.22M
Recent News
Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Cerus (CERS) have performed compared to their sector so far this year.
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG
Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, […]
3 Penny Stocks With Market Caps Under $500M And Promising Growth
Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying stocks that combine value and growth potential is key, especially when considering smaller or younger companies often referred to as penny stocks. Though the term may seem outdated, these investments can still offer significant opportunities for those looking to discover under-the-radar...
Cerebras IPO in focus as Nvidia earnings loom
Epistrophy Capital Research Chief Market Strategist and The Drill Down Podcast host Cory Johnson joins Market Catalysts to discuss the Cerebras IPO and key factors to watch in Nvidia’s (NVDA) upcoming earnings report.
Cerus Corporation Q1 2026 Earnings Call Summary
Moby summary of Cerus Corporation's Q1 2026 earnings call